Print

Promedior Announces Presentation of Data at Association for Research in Vision & Ophthalmology Demonstrating that Pentraxin-2 Suppresses Fibrosis, Neovascularization, and Vascular Leak in Retinal Disease Models  
5/1/2012 10:51:54 AM

MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, today announced that data from preclinical studies of recombinant human Pentraxin-2 (rPTX-2) will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held May 6-10, 2012, in Ft. Lauderdale, FL. The data to be presented highlight the efficacy of recombinant Pentraxin-2 in suppressing choroidal fibrosis and subretinal vascular leakage in independent models of age-related macular degeneration (AMD) and diabetic retinopathy, and confirm the potent effect of Pentraxin-2 on induction of regulatory macrophage activity in the retina.
//-->